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EDITORIAL
Why study membranous nephropathy in rats?
Membranous nephropathy (MN) is an important cause
of nephrotic syndrome and end-stage renal disease in
adults. The current treatment of this disease remains inad-
equate and nonspecific. To design more rationale therapy,
it would be useful if we really understood basic disease
pathophysiology. Since only limited information can be
obtained from the direct study of diseased humans, ani-
mal models are very helpful in our capacity to understand
pathogenesis. In the case of MN, we are fortunate to have
the accurate Heymann nephritis (HN) experimental MN
model in rats, which has been studied for almost 45 years.
What has the HN model taught us about the pathogen-
esis of MN? Initially, it was considered to be a disease in
which circulating immune complexes accumulated in the
subepithelial space. It later became clear that antibodies
were directed against intrinsic podocyte antigens, such
as the rat megalin–receptor associated protein (RAP)
complex, and that these antibodies progressively accumu-
lated over time to form the typical subepithelial immune
complexes. Complement activation by these podocyte-
associated immune complexes was required for protein-
uria to occur [1]. The classic study of Cybulsky et al [2]
showed that activation of C5b-9 was pathogenic and that
the podocyte was the focus of injury in experimental MN.
Subsequently, Kerjaschki et al [3] directly visualized the
insertion of C5b-9 into podocytes.
The concept that podocyte abnormalities could lead
to proteinuria underwent a resurgence with the discov-
ery of the podocyte protein nephrin, which is mutated
in congenital nephrotic syndrome [4]. Since then, a great
deal of effort has gone into defining the composition and
architecture of the podocyte slit diaphragm, and how ge-
netic abnormalities of slit diaphragm proteins can lead to
altered glomerular permselectivity [5]. It is likely that ac-
quired abnormalities of slit diaphragm proteins will have
similar consequence to these inherited conditions, which
is now an area of active research [6].
What happens to the slit diaphragm in HN? Early ultra-
structural studies clearly showed that the slit diaphragm
was altered in HN [7]. With the recent discovery of a
number of podocyte proteins, it has become possible to
be more specific about slit diaphragm events occurring in
HN. In previous work from the Salant lab [8], the quan-
tity of glomerular nephrin was reduced as the disease ad-
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vanced, which corresponded with its altered distribution.
Examining ZO-1- and CD2-associated proteins that were
not appreciably changed in HN showed that this was not
ubiquitous to all slit diaphragm proteins.
In this issue of Kidney International, Saran et al [9]
have gone one step further to define events occurring
in the slit diaphragm in HN. Here they have shown that
the redistribution and loss of nephrin requires comple-
ment activation. The presence of subepithelial immune
complexes was not sufficient to induce these abnormali-
ties alone—an intact complement system was necessary.
Furthermore, this reduced nephrin was attributable to a
diminished pool of nephrin associated with actin. Impor-
tantly, by studying early events, they were able to provide
evidence that the alteration in actin-associated nephrin
was a cause of proteinuria and not simply an effect of the
proteinuria.
Thus, the current paradigm for the pathogenesis of
HN has antibodies to podoctye proteins, such as to the
megalin-RAP complex, accumulating over time in subep-
ithelial immune deposits. Once a threshold amount of
antibody has accumulated [10], productive complement
activation ensues, leading to C5b-9 insertion into the
podocyte plasma membrane. Such C5b-9 insertion can
have a number of effects on the podocyte, including the
activation of specific signal pathways [11]. Relevant to the
slit diaphragm, there are several possible effects of C5b-9,
including ATP depletion, altered phosphorylation state
of nephrin, and a primary defect in podocyte actin. Irre-
spective of exact mechanism, the C5b-9–mediated disso-
ciation of nephrin from actin, its redistribution and loss
potentially into the urine [12] are associated with disrup-
tion of slit diaphragms and consequent proteinuria.
What is the relevance of HN in rats to MN in humans?
Clearly, the subepithelial deposits in human MN contain
immune complexes; the specific antigens, be they intrin-
sic podocyte proteins or extrinsic to the podocyte, have
been elusive. There is evidence that nephrin quantity is
reduced in MN [13, 14], comparable to what has been
shown in HN. Perhaps of greatest importance to clini-
cians concerns the C5b-9–mediated pathogenesis of HN.
Because the evidence was so compelling that C5b-9 was
relevant in rats, a multicenter study using a humanized
anti-C5 monoclonal antibody [15] has been completed.
Although there was no effect apparent in a short-term
study over 16 weeks, encouraging results were seen with
the one-year open-label extension of this study. For ex-
ample, the two nephrotic patients enrolled from our site
at the University of Chicago have gone into complete
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remission with anti-C5 treatment, and this has extended
beyond cessation of therapy. If these data stand up to
more careful study, we will have in hand a specific means
of treating human MN. This will have made the 45 years
of studying HN useful.
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